Overall, there were 31 cases (43%) with expression of CLDN18.2 in at least 40% of the TCs; the highest prevalence of cases with ≥40% TCs was in GC GS (77%), followed by GC EBV(+) (60%) and GC CIN (44%), while the prevalence amongst GC dMMR (33%) and GC EMT (20%) appeared lower. Here, CLDN18 is linked to cervical squamous intraepithelial neoplasia.